Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021

Tran, Van Nhi; Nguyen, Hoang An; Le, Thi Thanh An; Truong, Thanh; Nguyen, Phuong Thao; Nguyen, Thi Dieu Hien

doi:10.1016/j.vaccine.2021.09.060

Cited by 28 publications

(44 citation statements)

References 5 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Literature search initially yielded 1120 reports. After removal of duplicates and studies not focused on safety of COVID-19 vaccines, we reviewed nine clinical studies in full text [ 24 , 25 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ].…”

Section: Resultsmentioning

confidence: 99%

“…Among the remaining seven studies, we removed one study reporting a case series of vaccinated patients ( Figure 1 ) [ 24 ]. Thus, six studies entered the final analysis ( Table 2 ) [ 25 , 35 , 36 , 38 , 40 , 41 ]. Of these, two were cross-sectional surveys [ 25 , 40 ], three analyzed data from pharmacovigilance databases [ 36 , 38 , 41 ], and one evaluated BP after 15 min from vaccination among a cohort of patients and healthcare workers [ 35 ].…”

Section: Resultsmentioning

confidence: 99%

“…Proportions from surveys, specifically designed to evaluate BP changes after vaccination, was about 5% (5.06% in the analysis by Tran and co-workers [ 40 ] and 5.31% in the sample from Angeli and co-workers [ 25 ]).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis

Angeli

Reboldi

Trapasso

et al. 2022

JCDD

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) vaccines proved a strong clinical efficacy against symptomatic or moderate/severe COVID-19 and are considered the most promising approach for curbing the pandemic. However, some questions regarding the safety of COVID-19 vaccines have been recently raised. Among adverse events to vaccines and despite a lack of signal during phase III clinical trials, an increase in blood pressure (BP) after COVID-19 vaccination has been reported as a potential adverse reaction. We systematically analyze this topic and undertook a meta-analysis of available data to estimate the proportion of patients with abnormal BP or raise in BP after vaccination. Six studies entered the final analysis. Overall, studies accrued 357,387 subjects with 13,444 events of abnormal or increased BP. After exclusion of outlier studies, the pooled estimated proportion of abnormal/increased BP after vaccination was 3.20% (95% CI: 1.62–6.21). Proportions of cases of stage III hypertension or hypertensive urgencies and emergencies was 0.6% (95% CI: 0.1% to 5.1%). In conclusion, abnormal BP is not rare after COVID-19 vaccination, but the basic mechanisms of this phenomenon are still unclear and require further research.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis

Angeli

Reboldi

Trapasso

et al. 2022

JCDD

View full text Add to dashboard Cite

show abstract

“… 28 Similarly, our finding was comparable with findings from the Vietnamese study where female participants reported more AEFI. 39 Another study’s finding from Israel also supported this evidence by stating that females had nearly double risks of developing adverse events following 1st and 2nd dose of Pfizer-BioNTech COVID-19 vaccine as compared to males. 40 This may give clues for health professionals to give more attention to female vaccinees, and researchers to conduct further investigation on gender differences in terms of adverse events.…”

Section: Discussionmentioning

confidence: 88%

More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia

Muluneh¹,

Merid²,

Alemu³

et al. 2022

IDR

View full text Add to dashboard Cite

Background Ethiopia was using the ChAdOx1 COV-19 vaccine, and health professionals were targets of the first phase of the vaccination strategy. Evidence on the adverse events following immunization (AEFI) was barely available. The study aimed to assess the magnitude and associated factors of adverse events following ChAdOx1 COV-19 immunization among health professionals of the University of Gondar Specialized and Comprehensive Hospital, 2021. Methods An institution-based cross-sectional study was conducted among health professionals of the University of Gondar Comprehensive and specialized referral hospital. All health professionals who took the ChAdOx1 COV-19 vaccine in the 1st phase were surveyed. A total of 314 health professionals who took the ChAdOx1 COV-19 vaccine were included. The EpiData version 4.6.0.0 and Stata 16 were used for data entry and analysis, respectively. A binary logistic regression was used to identify statistically significant factors associated with AEFI. Chi-square and multicollinearity assumptions were tested. A p-value <0.2 and 0.05 were used as cut-off values of significance in the bi- and multivariable logistic regression models, respectively. An adjusted odds ratio (AOR) with 95% CI was reported for statistically significant variables. Results Among 314 study participants, 263 of them had at least one mild to severe AEFI of ChAdOx1 COV-19 with a prevalence of AEFI of 83.76% (95% CI: 79.23, 87.46). The commonest AEFI observed were injection site tenderness (n=198/263), fatigue (114/263), headache (n=107/263), and muscle pain (n=85/263). Females (AOR=2.75, 95% CI: 1.15, 6.58), and participants who felt the vaccine was unsafe (AOR=2.84, 95% CI: 1.03, 7.85) were having nearly three times more odds of AEFI immunization as compared to males and those who felt the vaccine was safe, respectively. Conclusion Adverse event following immunization has been a public health problem in Northwest Ethiopia. Being female and having a feeling that the vaccine is unsafe were statistically significantly associated with AEFI.

show abstract

“…After getting an AZD1222 shot, cases of hypertension were reported, mostly after 3 hours. 6 However, it should be noted that stage III hypertension caused by mRNA vaccines occurred only within minutes of the shot, which seems to be too short for cellular uptake and translation of mRNA, leading to the interaction between S protein and ACE2 receptors. 1 This may highlight the existence of other mechanisms rather than the downregulation of ACE2 receptors.…”

mentioning

confidence: 99%

Hypertensive Crisis Following COVID‐19 Vaccination

Khani

Entezari‐Maleki

2022

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021

Cited by 28 publications

References 5 publications

Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis

Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis

More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia

Hypertensive Crisis Following COVID‐19 Vaccination

Contact Info

Product

Resources

About